Pacific Biosciences of California IncPACB
Price$2.51

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $159.3M+3.4% YoYTTM through 30 Jun 2026
Net Income -$131.4MTTM through 30 Jun 2026
Free Cash Flow -$123.4MTTM through 30 Jun 2026

Margins

Current
Gross Margin34.5%
EBITDA Margin-79.0%
Operating Margin-22.5%
Net Margin-82.5%

Returns

-16.4%ROA

Balance Sheet Health

Debt / Equity269.63x
Current Ratio4.36x
Net Debt$371.1M
Cash & Equivalents$61M

Quality Metrics

Altman Z-Score-4.71
Piotroski F-Score4 / 9
FCF Margin-77.5%
Rule of 40-72.1
Earnings-Beat Rate100.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $160M
Diluted EPS-$0.42TTM
'19'20'21'22'23'24'25
FY2025: $-1.82

Dividend

No dividend

Capital Allocation

R&D Spend$88.4M
Capex Intensity3.4%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.